Honorable Myra Crownover, Chair, House Committee on Public Health
FROM:
Ursula Parks, Director, Legislative Budget Board
IN RE:
HB751 by Zerwas (relating to the prescription and pharmaceutical substitution of biological products; amending provisions subject to a criminal penalty.), Committee Report 1st House, Substituted
No significant fiscal implication to the State is anticipated.
The bill would amend the relating to the prescription and pharmaceutical substitution of biological products; amending provisions subject to a criminal penalty. Based on the analysis of the Board of Pharmacy, duties and responsibilities associated with implementing the provisions of the bill could be accomplished by utilizing existing resources.
Local Government Impact
No fiscal implication to units of local government is anticipated.